Dopaminagonist ny medicin för behandlingsresistent depression?

Pramipexole (Mirapex, Boehringer Ingelheim Pharmaceuticals, Inc), which is used to treat Parkinson's disease, can significantly improve symptoms of treatment-resistant depression, provided patients can tolerate the doses needed to achieve a therapeutic effect, new research suggests.

"These were quite treatment-refractory patients who did remarkably better on an adequately dosed dopamine agent," session co-chair Steven Hollon, PhD, Vanderbilt University, Nashville, Tennessee, told Medscape Medical News.

"The take-home message from this talk is that we should use a dopamine agent like pramipexole to deal with anhedonic treatment-refractory patients."